These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

234 related articles for article (PubMed ID: 30666606)

  • 1. Evaluating Antibody-Dependent Cell-Mediated Cytotoxicity by Chromium Release Assay.
    van der Haar Àvila I; Marmol P; Kiessling R; Pico de Coaña Y
    Methods Mol Biol; 2019; 1913():167-179. PubMed ID: 30666606
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluating Antibody-Dependent Cell-Mediated Cytotoxicity by Flow Cytometry.
    van der Haar Àvila I; Marmol P; Cany J; Kiessling R; Pico de Coaña Y
    Methods Mol Biol; 2019; 1913():181-194. PubMed ID: 30666607
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Natural killer cell cytotoxicity of breast cancer targets is enhanced by two distinct mechanisms of antibody-dependent cellular cytotoxicity against LFA-3 and HER2/neu.
    Cooley S; Burns LJ; Repka T; Miller JS
    Exp Hematol; 1999 Oct; 27(10):1533-41. PubMed ID: 10517495
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of ADAM10 and ADAM17 Inhibitors on Natural Killer Cell Expansion and Antibody-dependent Cellular Cytotoxicity Against Breast Cancer Cells
    Pham DH; Kim JS; Kim SK; Shin DJ; Uong NT; Hyun H; Yoon MS; Kang SJ; Ryu YJ; Cho JS; Yoon JH; Lee JS; Cho D; Lee SH; Park MH
    Anticancer Res; 2017 Oct; 37(10):5507-5513. PubMed ID: 28982863
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Paclitaxel enhances antibody-dependent cell-mediated cytotoxicity of trastuzumab by rapid recruitment of natural killer cells in HER2-positive breast cancer.
    Miura D; Yoneyama K; Furuhata Y; Shimizu K
    J Nippon Med Sch; 2014; 81(4):211-20. PubMed ID: 25186575
    [TBL] [Abstract][Full Text] [Related]  

  • 6. FcγRIIIb Restricts Antibody-Dependent Destruction of Cancer Cells by Human Neutrophils.
    Treffers LW; van Houdt M; Bruggeman CW; Heineke MH; Zhao XW; van der Heijden J; Nagelkerke SQ; Verkuijlen PJJH; Geissler J; Lissenberg-Thunnissen S; Valerius T; Peipp M; Franke K; van Bruggen R; Kuijpers TW; van Egmond M; Vidarsson G; Matlung HL; van den Berg TK
    Front Immunol; 2018; 9():3124. PubMed ID: 30761158
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A novel multiparametric flow cytometry-based cytotoxicity assay simultaneously immunophenotypes effector cells: comparisons to a 4 h 51Cr-release assay.
    Kim GG; Donnenberg VS; Donnenberg AD; Gooding W; Whiteside TL
    J Immunol Methods; 2007 Aug; 325(1-2):51-66. PubMed ID: 17617419
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Fc-optimized NKG2D-Fc constructs induce NK cell antibody-dependent cellular cytotoxicity against breast cancer cells independently of HER2/neu expression status.
    Raab S; Steinbacher J; Schmiedel BJ; Kousis PC; Steinle A; Jung G; Grosse-Hovest L; Salih HR
    J Immunol; 2014 Oct; 193(8):4261-72. PubMed ID: 25217158
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Elements related to heterogeneity of antibody-dependent cell cytotoxicity in patients under trastuzumab therapy for primary operable breast cancer overexpressing Her2.
    Varchetta S; Gibelli N; Oliviero B; Nardini E; Gennari R; Gatti G; Silva LS; Villani L; Tagliabue E; Ménard S; Costa A; Fagnoni FF
    Cancer Res; 2007 Dec; 67(24):11991-9. PubMed ID: 18089830
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of cryopreservation on effector cells for antibody dependent cell-mediated cytotoxicity (ADCC) and natural killer (NK) cell activity in (51)Cr-release and CD107a assays.
    Mata MM; Mahmood F; Sowell RT; Baum LL
    J Immunol Methods; 2014 Apr; 406():1-9. PubMed ID: 24561308
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Taxanes enhance trastuzumab-mediated ADCC on tumor cells through NKG2D-mediated NK cell recognition.
    Di Modica M; Sfondrini L; Regondi V; Varchetta S; Oliviero B; Mariani G; Bianchi GV; Generali D; Balsari A; Triulzi T; Tagliabue E
    Oncotarget; 2016 Jan; 7(1):255-65. PubMed ID: 26595802
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hepatitis C virus-induced NK cell activation causes metzincin-mediated CD16 cleavage and impaired antibody-dependent cytotoxicity.
    Oliviero B; Mantovani S; Varchetta S; Mele D; Grossi G; Ludovisi S; Nuti E; Rossello A; Mondelli MU
    J Hepatol; 2017 Jun; 66(6):1130-1137. PubMed ID: 28192188
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Charge variant analysis of proposed biosimilar to Trastuzumab.
    Dakshinamurthy P; Mukunda P; Prasad Kodaganti B; Shenoy BR; Natarajan B; Maliwalave A; Halan V; Murugesan S; Maity S
    Biologicals; 2017 Mar; 46():46-56. PubMed ID: 28087106
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Differential regulation of human monocytes and NK cells by antibody-opsonized tumors.
    Yin J; Albers AJ; Smith TS; Riddell GT; Richards JO
    Cancer Immunol Immunother; 2018 Aug; 67(8):1239-1250. PubMed ID: 29855696
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Interleukin-2 enhances the natural killer cell response to Herceptin-coated Her2/neu-positive breast cancer cells.
    Carson WE; Parihar R; Lindemann MJ; Personeni N; Dierksheide J; Meropol NJ; Baselga J; Caligiuri MA
    Eur J Immunol; 2001 Oct; 31(10):3016-25. PubMed ID: 11592078
    [TBL] [Abstract][Full Text] [Related]  

  • 16. V gamma 9 V delta 2 T cell cytotoxicity against tumor cells is enhanced by monoclonal antibody drugs--rituximab and trastuzumab.
    Tokuyama H; Hagi T; Mattarollo SR; Morley J; Wang Q; So HF; Moriyasu F; Nieda M; Nicol AJ
    Int J Cancer; 2008 Jun; 122(11):2526-34. PubMed ID: 18307255
    [TBL] [Abstract][Full Text] [Related]  

  • 17. An improved method to quantify human NK cell-mediated antibody-dependent cell-mediated cytotoxicity (ADCC) per IgG FcR-positive NK cell without purification of NK cells.
    Sung AP; Tang JJ; Guglielmo MJ; Redelman D; Smith-Gagen J; Bateman L; Hudig D
    J Immunol Methods; 2018 Jan; 452():63-72. PubMed ID: 29113954
    [TBL] [Abstract][Full Text] [Related]  

  • 18. An NK cell line (haNK) expressing high levels of granzyme and engineered to express the high affinity CD16 allele.
    Jochems C; Hodge JW; Fantini M; Fujii R; Morillon YM; Greiner JW; Padget MR; Tritsch SR; Tsang KY; Campbell KS; Klingemann H; Boissel L; Rabizadeh S; Soon-Shiong P; Schlom J
    Oncotarget; 2016 Dec; 7(52):86359-86373. PubMed ID: 27861156
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Canine non-B, non-T NK lymphocytes have a potential antibody-dependent cellular cytotoxicity function against antibody-coated tumor cells.
    Kim Y; Lee SH; Kim CJ; Lee JJ; Yu D; Ahn S; Shin DJ; Kim SK
    BMC Vet Res; 2019 Oct; 15(1):339. PubMed ID: 31610784
    [TBL] [Abstract][Full Text] [Related]  

  • 20. HER2-specific immunoligands engaging NKp30 or NKp80 trigger NK-cell-mediated lysis of tumor cells and enhance antibody-dependent cell-mediated cytotoxicity.
    Peipp M; Derer S; Lohse S; Staudinger M; Klausz K; Valerius T; Gramatzki M; Kellner C
    Oncotarget; 2015 Oct; 6(31):32075-88. PubMed ID: 26392331
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.